We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gentian Diagnostics Exhibits Assays for Wide Range of Clinical Chemistry Platforms at EUROMEDLAB

By LabMedica International staff writers
Posted on 11 Apr 2022

Gentian Diagnostics (Moss, Norway) exhibited its range of assays for highly relevant biomarkers for a wide range of clinical chemistry platforms at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EUROMEDLAB) in Munich, Germany.

Gentian demonstrated its Calprotectin Immunoassay (GCAL) assay, which is the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation. Calprotectin in plasma and serum is a sensitive and early biomarker in detection of inflammation and inflammatory response in infections. Calprotectin has been reported as diagnostic marker in the discrimination between bacterial and viral infection, in assessment of severe infections and sepsis and in the prediction for development of severe infections. Interestingly, calprotectin has also been reported a risk marker in severe COVID-19, which in contrast to other viral infection induces a hyperinflammation response and pathways mimic bacterial sepsis. Gentian’s GCAL is an open channel assay, meaning it can be added to all clinical chemistry analyzers.


Image: Gentian offers assays for highly relevant biomarkers for wide range of clinical chemistry platforms (Photo courtesy of Gentian Diagnostics)
Image: Gentian offers assays for highly relevant biomarkers for wide range of clinical chemistry platforms (Photo courtesy of Gentian Diagnostics)

Gentian also promoted its turbidimetric Cystatin C Immunoassay which is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro testing of cystatin C in human plasma and serum samples. Cystatin C is a superior glomerular filtration rate (GFR) marker for the diagnosis and therapeutic control of renal function1 for patients of all ages. The Cystatin C Immunoassay has documented high inter-instrument accuracy on a wide range of clinical chemistry analyzers. Gentian also promoted its new turbidimetric SARS-CoV-2 Total Antibody Immunoassay which is a quantitative antibody test that captures the full immune response detecting antibodies targeting the S1-subunit with high sensitivity and specificity. It will be calibrated against the international WHO international standard. Since the Gentian assay is platform agnostic, it can be seamlessly integrated in daily laboratory routine without additional infrastructure or workflow cost. The test follows a standard testing protocol utilizing existing logistic structure, from the routine blood test at the GP office to the clinical chemistry platforms with an assay time of only 10 minutes.

Related Links:
Gentian Diagnostics 


Gold Member
Turnkey Packaging Solution
HLX
Automated Blood Typing System
IH-500 NEXT
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay
New
Cortisol Rapid Test
Finecare Cortisol Rapid Quantitative Test

Latest EUROMEDLAB 2022 News

Sebia Displays Automated, High Throughput Capillary Electrophoresis (CE) Instruments at EUROMEDLAB 2022

Snibe Showcases Maglumi X3 Fully Automatic CLIA System at EUROMEDLAB 2022

Thermo Fisher Presents Cascadion SM Clinical Analyzer and LC-MS IVD Medical Devices at EUROMEDLAB 2022